Italy's Recordati post strong 2015 financial results

11 February 2016

Italian drugmaker Recordati (RECI: MI) today reported 2015 full-year results, showing that consolidated revenues were up 6.1% year-on-year at 1.05 billion euros ($1.17 billion). International sales, which represent 79.8% of total sales, grew by 8.8% while sales in Italy, at 20.2% of the total, decreasing by 3.3%.

Earnings before interest, taxes, depreciation and amortization (EBITDA) were 317.0 million, an increase of 15.8% over 2014, with a margin of 30.3% of sales thanks to gross margin improvement and the relatively low increase in operational costs. Operating income at 26.6% of sales, was 278.5 million euros, an increase of 20.6% over the preceding year. Net income increased 23.3% to 198.8 million euros.

Management comments

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK